Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".
| Autor: | Gómez JA; Vaccine Department, GlaxoSmithKline, Buenos Aires, Argentina., Pinto TJP; Vaccine Department, GlaxoSmithKline, Rio de Janeiro, Brazil., Guevara JN; Vaccine Department, GlaxoSmithKline, Panama City, Panama., Noronha TG; Institute of Technology for Immunobiologicals of Bio-Manguinhos, FIOCRUZ, Rio de Janeiro, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 31; Vol. 18 (1), pp. 1894898. Date of Electronic Publication: 2021 May 19. |
| DOI: | 10.1080/21645515.2021.1894898 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|